Exhibit 99.2
Lexaria Bioscience Files S4 Prospectus to Re-Domicile To Canada
Kelowna, British Columbia January 8, 2018 Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria) announces that, on January 5, 2018, it filed a registration statement and shareholder information circular on Form S-4 with the US Securities and Exchange Commission (the SEC) pursuant to which Lexaria will seek shareholder approval to change its corporate domicile from the State of Nevada to the Province of British Columbia, Canada, home of Lexarias operations and management.
The process of changing Lexarias corporate domicile, known as conversion in Nevada, or continuation in British Columbia, involves a number of steps including clearing the S-4 registration statement with the SEC, and seeking and obtaining shareholder approval at a meeting of the shareholders.
Chris Bunka, CEO and Chairman, commented the filing of the S-4 registration statement is the culmination of a long period of research and consideration by Lexarias management and board of directors. We look forward to working constructively with the SEC through its review of the S-4 and hope to announce a shareholder vote in a timely fashion.
Separately, Lexaria has received US$216,850.74 from the exercise of stock warrants and stock options previously granted. The stock options were exercised as to 33,375 at US$0.2273 and 50,000 at US$0.295. The warrants were exercised as to 324,191 at US$0.60. All exercises are by third parties who are neither officers nor directors of the Company.
No commissions or placement fees have been paid related to the funds received from these warrants exercised. Proceeds will be used for general corporate purposes.
The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
About Lexaria
Lexaria Bioscience Corp. has developed
and out-licenses its disruptive delivery technology that promotes healthier
ingestion methods, lower overall dosing and higher effectiveness of lipophilic
active molecules. Lexaria has multiple patents pending in over 40 countries
around the world and was granted its first patents in the USA and in Australia
related to edible forms of cannabinoids. Lexarias technology provides increases
in intestinal absorption rates; more rapid delivery to the bloodstream; and
important taste-masking benefits, for orally administered bioactive molecules
including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules.
www.lexariabioscience.com
For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp)
and on Facebook
http://tinyurl.com/y8vzcaam
FOR FURTHER
INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Alex Blanchard,
Communications Manager
(778) 796-1897
Or
NetworkNewsWire (NNW)
www.NetworkNewsWire.com
FORWARD-LOOKING STATEMENTS
This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"
"will," and other similar expressions are forward-looking statements, including
but not limited to: that any additional patent protection will be realized or
that patent achievements will deliver material results. Such forward-looking
statements are estimates reflecting the Company's best judgment based upon
current information and involve a number of risks and uncertainties, and there
can be no assurance that other factors will not affect the accuracy of such
forward-looking statements. This communication does not constitute an offer to
buy or sell or the solicitation of an offer to buy or sell any securities, or a
solicitation of any vote or approval. No offering of securities shall be made
except by means of a prospectus meeting the requirements of Section 10 of the
Securities Act of 1933, as amended. This communication relates to a proposed
change of corporate jurisdiction by Lexaria Bioscience Corp. In connection with
this proposed corporate action, Lexaria has filed and will file relevant
materials with the Securities Exchange Commission (the SEC) and applicable
Canadian securities regulatory authorities (Canadian Securities Commissions),
including the Lexaria registration statement on Form S-4 that will include a
proxy statement of Lexaria and constitute a prospectus of Lexaria. INVESTORS AND
SECURITY HOLDERS OF LEXARIA ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND
OTHER DOCUMENTS THAT MAY BE FILED WITH THE SEC AND THE CANADIAN SECURITIES
COMMISSIONS CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE
BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Any definitive proxy statement
(if and when available) will be mailed to stockholders of Lexaria. Investors and
security holders will be able to obtain free copies of these documents (if and
when available) and other documents filed with the SEC by Lexaria through the
website maintained by the SEC at www.sec.gov and, in the case of documents of
Lexaria filed with the Canadian Securities Commissions, on Lexarias SEDAR
profile on www.sedar.com. Copies of the documents filed with the SEC by Lexaria
will be available free of charge on Lexarias website at www.lexariabioscience.com, or by contacting Lexarias
Investor Relations Department by email info@lexariabioscience.com.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release